NIP
MRVI icon

Nicholas Investment Partners’s Maravai LifeSciences MRVI Stock Holding History

Nicholas Investment Partners’s Portfolio MRVI Stock Details MRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-227,823
Closed -$9.55M – 206
2021
Q4 		$9.55M Buy
+227,823
New +$9.23M 0.6% 61

Other funds holding MRVI

GL
GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $19.5B AUM 17.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OCBV
Ownership Capital B.V. Amsterdam, Netherlands $178M AUM 4.75% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Nicholas Investment Partners's MRVI Position: Q1 2022 in Review

Nicholas Investment Partners sold out of Maravai LifeSciences (MRVI) in Q1 2022, closing a stake of 227,823 shares — an estimated $9.55M sold.

Nicholas Investment Partners first reported a position in MRVI in Q4 2021 and held it in 1 quarter. The position peaked at $9.55M in Q4 2021. 235 funds tracked by Wall St. Rank hold MRVI as of Q1 2022.

  • Nicholas Investment Partners reported no remaining Maravai LifeSciences position as of Q1 2022 after selling out during the quarter.
  • Nicholas Investment Partners sold 227,823 Maravai LifeSciences shares in Q1 2022, an estimated $9.55M.
  • Nicholas Investment Partners first reported a position in Maravai LifeSciences in Q4 2021 and held it in 1 quarter.
  • Nicholas Investment Partners's Maravai LifeSciences position peaked at $9.55M in Q4 2021.
  • 235 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q1 2022.

Based on Nicholas Investment Partners's 13F filing for Q1 2022, filed 10 May 2022.